Department of Clinical Pharmacy, Deventer Hospital, Nico Bolkesteinlaan 75, 7416 SE, Deventer, the Netherlands.
Department of Internal Medicine, Deventer Hospital, Nico Bolkesteinlaan 75, 7416 SE, Deventer, the Netherlands.
Res Social Adm Pharm. 2020 Dec;16(12):1718-1723. doi: 10.1016/j.sapharm.2020.02.006. Epub 2020 Feb 22.
Pre-dialysis and dialysis patients are at risk for drug related problems (DRPs) due to a high incidence of comorbidities. Pharmacist-led medication reviews might reduce the number of DRPs.
The aim of this study was to evaluate pharmacist-led medication reviews in pre-dialysis and dialysis patients by determining the number and type of DRPs, nephrologist acceptance of pharmacist interventions and time investment.
From September 2017 until December 2018, pharmacist-led medication reviews were performed on pre-dialysis and dialysis patients. DRPs (medication discrepancies, prescribing issues related to drug and dose selection, drug use problems) were identified using the pharmacists' expert opinion and the STOPP/START criteria. Number and type of accepted pharmacist interventions, sustainability of interventions after at least 1 month and time investment were determined. Practical barriers in the process were appraised.
One-hundred twenty five patients were reviewed: 37 pre-dialysis and 88 dialysis patients. In 100 (80%) patients 277 medication discrepancies were identified of which 224 (81%) were accepted by the nephrologist. Pharmacists suggested 422 interventions concerning drug or dose selection for 115 patients; 106 interventions were accepted by the nephrologist, which resulted in 60 patients having medication changed. Ninety percent of those changes remained implemented on follow-up after at least 1 month. In 46 (37%) patients, the clinical pharmacist detected DRPs concerning the drug use process and performed patient counseling. The average time investment was 85 min per patient for the clinical pharmacist and 15 min for the nephrologist. Besides time investment, unclear responsibility for medication management due to multiple prescribers was an important barrier in the process and the main reason for nephrologists to reject pharmacist interventions.
Pharmacist-led medication reviews in pre-dialysis and dialysis patients led to medication changes in half of the patients. However, efficiency should be improved before adopting pharmacist-led medication reviews into clinical practice.
由于合并症的高发,透析前和透析患者存在药物相关问题 (DRP) 的风险。药剂师主导的药物审查可能会减少 DRP 的数量。
本研究旨在通过确定透析前和透析患者的 DRP 数量和类型、肾病医生对药剂师干预的接受程度以及时间投入,来评估药剂师主导的药物审查。
从 2017 年 9 月到 2018 年 12 月,对透析前和透析患者进行了药剂师主导的药物审查。使用药剂师的专业意见和 STOPP/START 标准,确定了药物差异、与药物和剂量选择相关的处方问题、药物使用问题等 DRP。确定了接受的药剂师干预措施的数量和类型、至少 1 个月后的干预措施的可持续性以及时间投入。评估了流程中的实际障碍。
共审查了 125 名患者:37 名透析前患者和 88 名透析患者。在 100 名(80%)患者中,发现了 277 种药物差异,其中 224 种(81%)被肾病医生接受。药剂师为 115 名患者提出了 422 种关于药物或剂量选择的干预措施;肾病医生接受了 106 项干预措施,导致 60 名患者的药物发生了变化。在至少 1 个月的随访中,这些变化的 90%仍然得到了实施。在 46 名(37%)患者中,临床药师发现了药物使用过程中的 DRP,并对患者进行了咨询。临床药师为每位患者投入的平均时间为 85 分钟,肾病医生投入的平均时间为 15 分钟。除了时间投入外,由于有多个开处方者,药物管理的责任不明确也是流程中的一个重要障碍,也是肾病医生拒绝药剂师干预的主要原因。
在透析前和透析患者中,由药剂师主导的药物审查导致一半患者的药物发生了变化。然而,在将药剂师主导的药物审查纳入临床实践之前,应该提高效率。